Merck patents on Hepatitis C treatment found valid in Gilead dispute

SAN JOSE (Reuters) – A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.


Reuters: Health News